The U.S. Food and Drug Administration said on Friday it had approved Stealth Biotherapeutics' once-daily injection for a rare, genetic disease that primarily affects males, making it the first ...
Stealth’s injection, known as elamipretide, will be sold as Forzinity for the treatment of Barth syndrome, an X-linked ...
More than a dozen people on Wednesday attended an open house in Sabillasville that was led by the U.S. Navy and local and state health officials to discuss testing private ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback